Acelyrin Inc (NASDAQ: SLRN) on Tuesday, soared 12.39% from the previous trading day, before settling in for the closing price of $2.18. Within the past 52 weeks, SLRN’s price has moved between $1.85 and $7.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 40.53%. With a float of $73.15 million, this company’s outstanding shares have now reached $100.45 million.
The extent of productivity of a business whose workforce counts for 83 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Acelyrin Inc (SLRN) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Acelyrin Inc is 27.51%, while institutional ownership is 75.92%. The most recent insider transaction that took place on Mar 17 ’25, was worth 49,354. In this transaction Chief Executive Officer of this company sold 17,986 shares at a rate of $2.74, taking the stock ownership to the 671,753 shares. Before that another transaction happened on Mar 17 ’25, when Company’s Chief Legal Officer sold 3,913 for $2.74, making the entire transaction worth $10,737. This insider now owns 121,587 shares in total.
Acelyrin Inc (SLRN) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 40.53% per share during the next fiscal year.
Acelyrin Inc (NASDAQ: SLRN) Trading Performance Indicators
Acelyrin Inc (SLRN) is currently performing well based on its current performance indicators. A quick ratio of 18.10 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.50 and is forecasted to reach -1.33 in one year’s time.
Technical Analysis of Acelyrin Inc (SLRN)
The latest stats from [Acelyrin Inc, SLRN] show that its last 5-days average volume of 0.51 million was inferior to 1.9 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 45.53%. Additionally, its Average True Range was 0.17.
During the past 100 days, Acelyrin Inc’s (SLRN) raw stochastic average was set at 23.09%, which indicates a significant decrease from 90.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.35% in the past 14 days, which was lower than the 105.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.47, while its 200-day Moving Average is $3.96. Now, the first resistance to watch is $2.57. This is followed by the second major resistance level at $2.69. The third major resistance level sits at $2.90. If the price goes on to break the first support level at $2.25, it is likely to go to the next support level at $2.04. Assuming the price breaks the second support level, the third support level stands at $1.92.
Acelyrin Inc (NASDAQ: SLRN) Key Stats
Market capitalization of the company is 247.22 million based on 100,907K outstanding shares. Right now, sales total 0 K and income totals -248,230 K. The company made 0 K in profit during its latest quarter, and -79,030 K in sales during its previous quarter.
